TrametinibMeSH Supplementary Concept

https://www.has-sante.fr/jcms/p_3515581/fr/finlee-spexotras-dabrafenib-trametinib-gliome-pediatrie
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic combined chemotherapy protocols
dabrafenib
protein kinase inhibitors
antineoplastic agents
child
infant
Childhood Low Grade Glioma
malignant glioma
Childhood Malignant Glioma
BRAF V600E Mutation Present
guidelines for drug use
package leaflet
summary of product characteristics
Trametinib Dimethyl Sulfoxide
administration, oral
trametinib
evaluation of the transparency committee
dabrafenib
Dabrafenib/Trametinib Regimen
glioma
trametinib

---
https://ansm.sante.fr/tableau-acces-derogatoire/trametinib
2024
false
false
false
France
French
summary of product characteristics
package leaflet
administration, oral
Powder for Oral Solution Dosage Form
child
guidelines for drug use
trametinib
trametinib
drug information
glioma
BRAF Inhibitor

---
https://www.ema.europa.eu/en/medicines/human/EPAR/spexotras
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
trametinib
trametinib
antineoplastic agents
protein kinase inhibitors
administration, oral
drug approval
Trametinib Dimethyl Sulfoxide
orphan drug production
infant
child
europe
trametinib
antineoplastic combined chemotherapy protocols
glioma
Dabrafenib/Trametinib Regimen
Childhood Malignant Glioma
Childhood Low Grade Glioma
malignant glioma
glioma
BRAF V600E Mutation Present
Mitogen-Activated Protein Kinase Kinase Inhibitor
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3450970/en/dabrafenib-trametinib-novartis-dabrafenib-trametinib-gliome-pediatrie
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infant
child
malignant glioma
BRAF V600E Mutation Present
Low Grade Glioma
administration, oral
dabrafenib
trametinib
protein kinase inhibitors
antineoplastic agents
guidelines for drug use
Dabrafenib/Trametinib Regimen
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
trametinib
dabrafenib
glioma

---
https://www.has-sante.fr/jcms/p_3381101/fr/tafinlar-mekinist-dabrafenib/-trametinib
2022
France
evaluation of the transparency committee
trametinib
trametinib

---
https://www.has-sante.fr/jcms/p_3146424/fr/tafinlar-mekinist
2020
false
false
false
France
BRAF V600E mutation positive
dabrafenib
dabrafenib
treatment outcome
antineoplastic combined chemotherapy protocols
trametinib
antineoplastic agents
protein kinase inhibitors
trametinib
carcinoma, non-small-cell lung
BRAF protein, human
evaluation of the transparency committee
imidazoles
oximes
pyridones
pyrimidinones
proto-oncogene proteins b-raf

---
https://www.has-sante.fr/portail/jcms/c_2911595/fr/mekinist-tafinlar
2019
false
true
false
false
France
trametinib
dabrafenib
treatment outcome
melanoma
administration, oral
antineoplastic combined chemotherapy protocols
adult
antineoplastic agents
protein kinase inhibitors
melanoma
BRAF V600 Mutation
evaluation of the transparency committee
pyridones
pyrimidinones
imidazoles
oximes

---
https://www.has-sante.fr/portail/jcms/c_2835407/fr/mekinist-tafinlar
https://www.has-sante.fr/portail/jcms/c_2835407/fr/tafinlar-dabrafenib-en-association-a-mekinist-trametinib-inhibiteurs-de-la-proteine-kinase
2018
false
false
false
false
France
French
evaluation of the transparency committee
dabrafenib
dabrafenib
antineoplastic combined chemotherapy protocols
treatment outcome
administration, oral
carcinoma, non-small-cell lung
BRAF V600 Mutation
trametinib
trametinib
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
guidelines for drug use
pyridones
pyrimidinones
pyridones
pyrimidinones
imidazoles
oximes
imidazoles
oximes

---
The risk of colitis and gastrointestinal perforation has been added to the Warnings and Precautions and Adverse Reactions sections of the Canadian product monograph for Mekinist (trametinib)
http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2017-01-page4-fra.php#pmu
2017
false
false
false
Canada
French
English
pharmacovigilance note
administration, oral
journal article
trametinib
risk factors
trametinib
Digestive System Perforation
intestinal perforation
colitis
socioeconomic factors
pyridones
pyrimidinones

---
http://www.has-sante.fr/portail/jcms/c_2606857/fr/mekinist
http://www.has-sante.fr/portail/jcms/c_2606857/fr/mekinist-trametinib-inhibiteur-de-proteine-kinase
2016
false
false
false
France
French
evaluation of the transparency committee
administration, oral
trametinib
trametinib
trametinib
adult
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
melanoma
neoplasm metastasis
Metastatic Melanoma
Unresectable Malignant Neoplasm
melanoma
MAP kinase kinase 1
MAP kinase kinase 2
mutation
proto-oncogene proteins b-raf
dabrafenib
guidelines for drug use
Tyrosine Kinase Inhibitors
pyridones
pyrimidinones
pyridones
pyrimidinones
imidazoles
oximes

---
https://www.ema.europa.eu/medicines/human/EPAR/Mekinist
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
trametinib
drug approval
europe
trametinib
trametinib
adult
melanoma
antineoplastic agents
antineoplastic agents
mutation
proto-oncogene proteins b-raf
administration, oral
drug monitoring
product surveillance, postmarketing
aged
drug interactions
contraception
pregnancy
breast feeding
protein kinase inhibitors
protein kinase inhibitors
MAP kinase kinase 1
MAP kinase kinase 2
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
pyridones
pyrimidinones
pyridones
pyrimidinones

---